DEMECAN

Berlin, Germany Founded: 2017 • Age: 9 yrs
Producer of medical cannabis

About DEMECAN

DEMECAN is a Healthcare company based in Berlin (Germany) founded in 2017 by Constantin Von Der Groeben, Adrian Fischer, and Cornelius Maurer. Producer of medical cannabis. DEMECAN has raised $7.64 million across 1 funding round from investors including b2venture. Its website demecan.de draws about 22 thousand monthly visits. DEMECAN offers products and services including Medical Cannabis Products, Patientenausweis, and Apotheken-Finder. Its focus areas include HealthTech, Cannabis HealthTech and Nutraceuticals.

Company details

DEMECAN, backed by 7641380.0 from b2venture, focuses on healthtech, cannabis healthtech, providing healthcare solutions, and nutraceuticals. Producer of medical cannabis. Driving innovation, growth, and excellence in its industry sectors. It continues to evolve, meeting industry challenges with strategic approaches.

  • Headquarters Berlin, Germany
  • Founders Constantin Von Der Groeben, Adrian Fischer, Cornelius Maurer
  • Sectors
    Healthcare
  • Website category Health · Addictions
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website demecan.de
  • Social LinkedIn X Instagram
Key Metrics
  • Total Equity Funding
    $7.64M (USD)

    in 1 rounds

  • Latest Funding Round
    $7.64M (USD), Series A

    Oct 2019

  • Investors

Products & Services of DEMECAN

DEMECAN offers a comprehensive portfolio of products and services, including Medical Cannabis Products, Patientenausweis, and Apotheken-Finder.

Medical Cannabis Products
Pharmaceuticals

High-quality cannabis for medical therapy and patient treatment

Patientenausweis
Digital Services

Secure digital ID for identifying medical cannabis patients

Apotheken-Finder
Information Services

Tool to locate pharmacies offering cannabis-related services

Funding Insights of DEMECAN

DEMECAN has successfully raised a total of $7.64M through 1 strategic funding round. The most recent funding activity was a Series A round of $7.64 million completed in October 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $7.64M
  • Total Rounds 1
  • Last Round Series A β€” $7.64M
  • First Round $7.64M

    (Oct 2019)

  • Investors Count 1

All 1 funding rounds of DEMECAN with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Oct 2019$7.64MSeries A–b2venture
–
Valuation history

1 investors in total: 1 institutional.

Investors in DEMECAN

DEMECAN has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include b2venture.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Venture capital is provided to innovative startups by b2venture.
b2venture.vcSt. Gallen, Switzerland
Premium access

Investor details for DEMECAN

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of DEMECAN

9 people are tracked at DEMECAN (4 in leadership, 4 in board & advisors, 1 in team).

NameRoleGroup
Constantin Von Der Groeben
Co-Founder & Managing DirectorLeadership
Adrian Fischer
Co-Founder & Managing DirectorLeadership
Cornelius Maurer
Co-Founder & Managing DirectorLeadership
Dr. Cornelius Maurer
Founder & Board MemberLeadership
Dennis Stracke
AdvisorBoard & advisors
Thomas Herdegen
AdvisorBoard & advisors
Kirsten Müller-Vahl
AdvisorBoard & advisors
Joachim Nadstawek
AdvisorBoard & advisors
Valentin Rieß
Motherplant and Propagation ManagerTeam
Premium access

Complete people profiles for DEMECAN

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of DEMECAN

2 dated milestones of DEMECAN across 2 years, from founding to its latest funding, stage changes and deals.

  1. Founded DEMECAN is founded.
  2. Funding First funding round of $7.6M.

Web traffic of DEMECAN

The website of DEMECAN (demecan.de) receives about 21.8K visits a month and ranks #2,684,830 among all websites worldwide, #2,912 in Addictions.

  • Monthly visits
    21.8K

    ▲ 150.7% vs previous month

  • Unique visitors
    4.7K

    per month

  • Global rank
    #2,684,830

    among all websites

  • Category rank
    #2,912

    Health · Addictions

Similar websites

Websites whose visitors overlap most with DEMECAN. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
canifyclinics.com
canifyclinics.com
100%
#1,429,528–
cannalivery.com
cannalivery.com
98%
#2,507,004–
cann24.de
cann24.de
94%
#1,875,852–
avaay.de
93%
102.3K#525,140View details
gruenebluete.de
gruenebluete.de
89%
–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 20 similar websites and full traffic analytics for DEMECAN

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 20 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Demecan

Premium access

Complete news archive for DEMECAN

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about DEMECAN

DEMECAN was founded in 2017 and raised its 1st funding round 2 years after it was founded.

DEMECAN is headquartered in Berlin, Germany. It is registered at Berlin, Berlin, Germany.

DEMECAN is a funded company, having raised a total of $7.64M across 1 funding round to date. The company's 1st funding round was a Series A of $7.64M, raised on Oct 2019.

DEMECAN, backed by 7641380.0 from b2venture, focuses on healthtech, cannabis healthtech, providing healthcare solutions, and nutraceuticals. Producer of medical cannabis. Driving innovation, growth, and excellence in its industry sectors. It continues to evolve, meeting industry challenges with strategic approaches.

DEMECAN offers Medical Cannabis Products, Patientenausweis, and Apotheken-Finder.

DEMECAN has 1 investor. Key investors include b2venture.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available